APA

Duployez N., Grzych G., Ducourneau B., Alarcon Fuentes, Grardel N., Boyer T., Abou Chahla W., Bruno B., Nelken B., Clappier E. & Preudhomme C. (20170109). NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors. : Haematologica.

Chicago

Duployez Nicolas, Grzych Guillaume, Ducourneau Benoît, Alarcon Fuentes, Grardel Nathalie, Boyer Thomas, Abou Chahla Wadih, Bruno Bénédicte, Nelken Brigitte, Clappier Emmanuelle and Preudhomme Claude. 20170109. NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors. : Haematologica.

Harvard

Duployez N., Grzych G., Ducourneau B., Alarcon Fuentes, Grardel N., Boyer T., Abou Chahla W., Bruno B., Nelken B., Clappier E. and Preudhomme C. (20170109). NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors. : Haematologica.

MLA

Duployez Nicolas, Grzych Guillaume, Ducourneau Benoît, Alarcon Fuentes, Grardel Nathalie, Boyer Thomas, Abou Chahla Wadih, Bruno Bénédicte, Nelken Brigitte, Clappier Emmanuelle and Preudhomme Claude. NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors. : Haematologica. 20170109.